State of Alaska Department of Revenue Purchases 4,399 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

State of Alaska Department of Revenue boosted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 79.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,929 shares of the specialty pharmaceutical company’s stock after buying an additional 4,399 shares during the period. State of Alaska Department of Revenue’s holdings in Supernus Pharmaceuticals were worth $427,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. Juncture Wealth Strategies LLC increased its stake in shares of Supernus Pharmaceuticals by 0.8% in the first quarter. Juncture Wealth Strategies LLC now owns 51,459 shares of the specialty pharmaceutical company’s stock worth $1,611,000 after buying an additional 433 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Supernus Pharmaceuticals by 4.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,107,007 shares of the specialty pharmaceutical company’s stock worth $27,952,000 after buying an additional 51,511 shares during the last quarter. Virginia Retirement Systems ET AL increased its stake in shares of Supernus Pharmaceuticals by 17.1% in the first quarter. Virginia Retirement Systems ET AL now owns 71,800 shares of the specialty pharmaceutical company’s stock worth $2,247,000 after buying an additional 10,500 shares during the last quarter. Turner Investments LLC bought a new stake in Supernus Pharmaceuticals during the first quarter valued at about $219,000. Finally, Bank of America Corp DE increased its stake in Supernus Pharmaceuticals by 10.7% in the first quarter. Bank of America Corp DE now owns 362,952 shares of the specialty pharmaceutical company’s stock valued at $11,361,000 after buying an additional 35,069 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ SUPN) traded down 0.69% during midday trading on Friday, hitting $43.20. The company had a trading volume of 626,131 shares. The firm’s 50-day moving average is $42.56 and its 200-day moving average is $34.77. Supernus Pharmaceuticals, Inc. has a 12-month low of $17.25 and a 12-month high of $46.45. The firm has a market capitalization of $2.19 billion, a P/E ratio of 21.80 and a beta of 1.31.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. The business had revenue of $75.83 million for the quarter, compared to analyst estimates of $68.54 million. On average, analysts predict that Supernus Pharmaceuticals, Inc. will post $1.04 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.com-unik.info/2017/08/19/state-of-alaska-department-of-revenue-raises-stake-in-supernus-pharmaceuticals-inc-nasdaqsupn-updated-updated-updated.html.

Several analysts have issued reports on the company. BidaskClub downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Jefferies Group LLC restated a “buy” rating and set a $51.00 price objective on shares of Supernus Pharmaceuticals in a report on Friday, August 4th. Janney Montgomery Scott began coverage on Supernus Pharmaceuticals in a report on Friday, July 14th. They issued a “neutral” rating and a $47.00 target price on the stock. Cowen and Company reiterated a “positive” rating and issued a $50.00 target price (up previously from $40.00) on shares of Supernus Pharmaceuticals in a report on Thursday, August 3rd. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $47.00 target price (up previously from $36.00) on shares of Supernus Pharmaceuticals in a report on Tuesday, July 18th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $48.43.

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 3,709 shares of the business’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $45.23, for a total transaction of $167,758.07. Following the transaction, the vice president now owns 17,500 shares of the company’s stock, valued at approximately $791,525. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Padmanabh P. Bhatt sold 5,500 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $34.90, for a total value of $191,950.00. Following the transaction, the vice president now directly owns 43,887 shares in the company, valued at approximately $1,531,656.30. The disclosure for this sale can be found here. In the last three months, insiders sold 28,000 shares of company stock worth $1,130,524. 6.70% of the stock is owned by insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

What are top analysts saying about Supernus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit